Efficacy and safety of two administration modes of an intra‐detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo‐controlled phase IIa study

• Published in: Neurourology and urodynamics Vol. 36; no. 2; pp. 457 - 462
• Main Authors: Denys, Pierre, Del Popolo, Giulio, Amarenco, Gerard, Karsenty, Gilles, Le Berre, Philippe, Padrazzi, Bruno, Picaut, Philippe
• Format: Journal Article
• Language: English
• Published: United States 01.02.2017
• Subjects: Acetylcholine Release Inhibitors - administration & dosage; Acetylcholine Release Inhibitors - adverse effects; Acetylcholine Release Inhibitors - therapeutic use; Adult; Botulinum Toxins, Type A - administration & dosage; Botulinum Toxins, Type A - adverse effects; Botulinum Toxins, Type A - therapeutic use; botulinum toxin‐A; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; incontinence episode frequency; Male; Middle Aged; neurogenic overactive bladder; Pilot Projects; Quality of Life; Treatment Outcome; Urinary Bladder, Neurogenic - drug therapy; Urinary Bladder, Neurogenic - physiopathology; Urinary Bladder, Overactive - drug therapy; Urinary Bladder, Overactive - physiopathology; Urodynamics - drug effects; Urodynamics - physiology; botulinum toxin-A; neurogenic overactive bladder; quality of life; incontinence episode frequency
• ISSN: 0733-2467; 1520-6777
• DOI: 10.1002/nau.22954

Aims Assess the efficacy and safety of abobotulinumtoxinA (Dysport®) in adult patients with neurogenic detrusor overactivity (NDO). Methods This Phase IIa, international, multicentre, double‐blind, randomised, placebo controlled, pilot study enrolled 47 patients with NDO and urinary incontinence resulting from spinal cord injury (SCI) or multiple sclerosis (MS). Patients were treated with 15 intra‐detrusor injections of Dysport 750 U or the equivalent placebo (n = 16 and 7) or 30 injections of Dysport 750 U or the equivalent placebo (n = 17 and 7). Primary endpoint was change from baseline in mean number of daily incontinence episode frequency (IEF) at day 84. Secondary endpoints included change from baseline in urodynamic parameters and quality of life (QOL). A safety assessment was also conducted. Results Adjusted mean changes from baseline in IEF were −3.2 (−76%) and −1.7 (−15%) for 15 injections Dysport and placebo groups, respectively, (P = 0.1103) and −3.2 (−88%) and −2.6 (−73%) for 30 injections Dysport and placebo groups, respectively, (P = 0.0686). Statistically significant improvements in maximum cystometric capacity, maximum detrusor pressure and volume at first contraction were reported in the Dysport groups compared with placebo (P < 0.05). Improvements in QOL were reported. Three muscle weakness episodes were reported as serious adverse events in two tetraplegic and one paraplegic patient, all in the 15 injections Dysport group. Conclusions Both 15 and 30 injections administration modes of Dysport decreased daily IEF and resulted in significant improvements in urodynamic parameters in NDO patients with MS or SCI. Reduction to 15 injection sites did not appear to be associated with any impact on efficacy. Neurourol. Urodynam. 36:457–462, 2017. © 2016 Wiley Periodicals, Inc.